Funding
← Back to your selection

Venrock Healthcare Capital Partners

Activity from announced rounds

All recorded activity
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$645M
3 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1
Series C+1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in all activity
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D
Role not disclosed
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B
Role not disclosed